Market Size – USD 243.0 Million in 2019, Market Growth - CAGR of 22.0%, Market Trends – Risingprominence ofhuman microbiome therapeutics.
The newest report compiled by Emergen Research, titled ‘Global Human Microbiome Therapeutics Market Forecast to 2027,’ serves as an appropriate prototype of the global Human Microbiome Therapeutics market. The latest study offers critical details on the market’s ongoing trends and latest developments. The report endows the reader with a panoramic view of the Human Microbiome Therapeutics industry, simultaneously offering viable insights into the anticipated market size, revenue share, and sales & distribution networks.
These
insights are bound to help readers visualize the key outcomes of this industry
in the near future and take necessary measures to stand tall, even during times
as challenging as the current COVID-19 crisis. Venture capitalists and the key
businesses involved in this sector are the primary addressees of this report,
which is intended to assist them in decision-making and formulating productive
business plans.
In the later segment of this report, our team of market researchers hasholistically covered the profound impact of the COVID-19 pandemic on the global Human Microbiome Therapeutics market. The outbreak has resulted in several dramatic changes in the current Human Microbiome Therapeutics business sphere, wreaking a significant financial crunch for the leading vendors and producers in this industry. Furthermore, the report elaborates on the current financial positions of the key market players in the present market situation. The report concludes with vital data and information pertaining to the global market growth on both regional and global levels.
To
understand geography trends, download Sample Report@ https://www.emergenresearch.com/request-sample-form/280
In August 2019, BiomX Ltd. completedthe construction
of a state-of-the-art production facility in Ness Ziona. The new site will be a
hub for the clinical development of candidate phage products for the company
and might be extended in the future to accommodate commercial manufacturing
requirements. This development marks a significant phase in clinical
development in the current scenario of live biotherapeutics, involvingphagesas
well as human-derived cells and bacteria.
In the forecast period, the probiotics segment is speculated
to dominate the human microbiome therapeutics market. Probiotics are organisms
like bacteria and yeasts, the consumption of which has various health benefits.
The small molecule therapies segment held the
largest market share in 2019, and due to its broad scope of application, it is
predicted to deliver the highest growth rate in the forecast period.
Over the forecast timeframe, the infectious disease
segment is projected to dominate the industry. Potential development in the
segment is driven by the mounting prevalence of microbial dysbiosis-based
diseases with the extensive application of antibiotics and advancement of
microbiome-based treatments.
Owing to the surge in dietary supplement
consumption in the region, North America is estimated to lead the global human
microbiome therapeuticsmarket. Additionally, technologically specialized
research facilities dedicated todeveloping experimental therapeutics, the
expanding health-conscious consumer base, and escalating healthcare expenditure
would also contribute to the region’s dominance.
Key participants include BiomX Ltd., Embion
Technologies SA, LNC Therapeutics SA, DermBiont, Inc, CommenseInc, Oxidien
Pharmaceuticals, LLC, Carbiotix AB, Biotagenics Inc., Finch Therapeutics, and CoreBiome,
Inc., among others.
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/human-microbiome-therapeutics-market
Emergen
Research has bifurcated the Global Human Microbiome Therapeutics Market based
on product, approach, therapeutic area, disease, and region:
Product Outlook (Revenue, USD Million; 2017-2027)
Prescription
Drugs
Medical
Foods
Probiotics
Prebiotics
Approach Outlook (Revenue, USD
Million; 2017-2027)
Microbial
Consortia
Small
Molecule Therapies
Phage
Cocktail
Microbial
Ecosystems
Single
Strain Whole Bacteria
Genetically
Modified Single Strain Bacteria
Therapeutic Area Outlook (Revenue, USD Million;
2017-2027)
Oncology
Dermatological
Disorders
Autoimmune
Disorders
Infectious
Disease
Metabolic
Disorders
Others
Disease Outlook (Revenue, USD
Million; 2017-2027)
Diabetes
difficile
Crohn’s
Disease
Irritable
Bowel Syndrome
Others
Regional Outlook (Revenue, USD
Million; 2017-2027)
o
North America
1.
U.S.
2.
Canada
3.
Mexico
o
Europe
1.
Germany
2.
U.K.
3.
France
4.
BENELUX
5.
Rest of Europe
o
Asia Pacific
1.
China
2.
Japan
3.
South Korea
4.
India
5.
Rest of APAC
o
Latin America
1.
Brazil
2.
Rest of LATAM
o
Middle East &Africa
1.
Saudi Arabia
2.
U.A.E.
3.
Rest of MEA
No comments:
Post a Comment